Regulatory & Legal

The aerial firefighting giant lands a major DOI contract for Alaskan transport, signaling a strategic shift into year-round government logistics.

The neurohealth firm surpassed revenue estimates and hit positive cash flow, but a dynamic competitive landscape and CEO transition loom ahead of its earnings call.

A new deal brings Nanox's low-radiation, cost-effective Nanox.ARC to orthopedic clinics, aiming to reshape point-of-care diagnostics in the region.

A new partnership between Dstillery, Keynes, and The Trade Desk cuts a 48-hour workflow to 5 minutes, heralding a new era of autonomous AI in advertising.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

As shadow AI and autonomous agents create huge risks, Teramind's new platform offers total visibility to help firms innovate without sacrificing security.

A new poll shows 81% of South Carolinians back energy choice for industry, but critics fear it could leave homeowners paying more for power.

As SIGA prepares to unveil its 2025 financials, investors are focused on the future of its Tpoxx contracts and its role in global biodefense strategy.

A new survey reveals a silent public health crisis as millions of Canadians face chronic sleep loss, with many admitting to driving while dangerously tired.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

Axxess's upcoming conference tackles AI's role in home health, unveils a new leadership certification, and honors an industry titan. Here's what it means.

The digital asset giant is delisting from Toronto to streamline costs, a move that reshapes its buyback plan and how Canadian investors trade its stock.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

A new trial for a cell therapy targeting a rare eye disease offers hope, driven by a patient-advocate's journey and with potential to treat common AMD.

Esperion's $75M+ deal for Corstasis and its novel nasal diuretic, Enbumyst, targets a $4B market and a new era of at-home edema management.

A new report reveals Canadians are overwhelmed by scams, making them vulnerable to AI-driven fraud. Is a national strategy enough to fight back?

A €21.5M consortium is launching clinical trials for AI that assists in brain and cancer surgery, aiming to ease a critical European doctor shortage.

Transcelestial unveils CENTAURI+, a laser net with AI healing, 40Gbps speeds, and quantum-safe security to solve the world's bandwidth crisis.

Post-listing, the Swiss HealthTech firm pushes for US market expansion and European reimbursement, streamlining its focus on AI-powered brain health.

The inaugural Harsha Parekh Librarian Awards celebrate the vital, often overlooked role of librarians in shaping India's next generation of readers.